A nomogram to predict the prognosis of advanced soft tissue sarcoma patients treated with anlotinib: A real-world population-based study.

被引：0
|
作者：
Bin Wang
Liu, Jie
Zhang, Ren Shu
Jiang, Yu
机构：
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23550
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of anlotinib for advanced SCLC patients: A real-world study.
    Yao, Yu
    He, Xiaopeng
    Hou, Xinli
    Liao, Hehe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
    Liu, Jiayong
    Bai, Chujie
    Li, Shu
    Xue, Ruifeng
    Gao, Tian
    Zhang, Lu
    Tan, Zhichao
    Fang, Zhiwei
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (04)
  • [3] Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
    Boye, Kjetil
    Lobmaier, Ingvild
    Kobbeltvedt, Marthe Rosvoll
    Thorkildsen, Joachim
    Taksdal, Ingeborg
    Bjerkehagen, Bodil
    Bruland, oyvind S.
    Zaikova, Olga
    Sundby Hall, Kirsten
    Hompland, Ivar
    ACTA ONCOLOGICA, 2022, 61 (07) : 793 - 800
  • [4] Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.
    Jerzak, Katarzyna Joanna
    Rosen, Michael
    Wang, Xin Y.
    Chehade, Rania
    Zhang, Bo
    Saskin, Refik
    Das, Sunit
    Soliman, Hany
    Sahgal, Arjun
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A nomogram to predict prognosis of patients with lung adenosquamous carcinoma: a population-based study
    Liang, Jiaqi
    Sui, Qihai
    Zheng, Yuansheng
    Bi, Guoshu
    Chen, Zhencong
    Li, Ming
    Huang, Yiwei
    Lu, Tao
    Zhan, Cheng
    Guo, Weigang
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2288 - +
  • [6] The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era
    Zhang, Ren-Shu
    Liu, Jie
    Deng, Yao-Tiao
    Wu, Xin
    Jiang, Yu
    CANCER MEDICINE, 2022, 11 (11): : 2271 - 2283
  • [7] Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma
    de Sande Gonzalez, Luis Miguel
    Martin-Broto, Javier
    Kasper, Bernd
    Blay, Jean-Yves
    Le Cesne, Axel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (11) : 957 - 963
  • [8] Anlotinib, a multitarget tyrosine kinase inhibitor, for advanced lung cancer patients: Efficacy in real-world study.
    Feng, Jifeng
    Qian, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Real-World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center
    Wilson, Isabella
    Strach, Madeleine
    Bhadri, Vivek
    Harrison, Michelle
    Tang, Whiter
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [10] Pazopanib treatment outcome in advanced soft tissue sarcoma: Real-world data
    Alshamsan, B.
    Alshibany, A.
    Badran, A.
    Maraiki, F.
    Elshenawy, M. A.
    Elhassan, T.
    Atallah, J. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S987 - S987
12345